These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. MRI versus ⁶⁸Ga-PSMA PET/CT for gross tumour volume delineation in radiation treatment planning of primary prostate cancer. Zamboglou C, Wieser G, Hennies S, Rempel I, Kirste S, Soschynski M, Rischke HC, Fechter T, Jilg CA, Langer M, Meyer PT, Bock M, Grosu AL. Eur J Nucl Med Mol Imaging; 2016 May; 43(5):889-897. PubMed ID: 26592938 [Abstract] [Full Text] [Related]
6. Evaluation of intensity modulated radiation therapy dose painting for localized prostate cancer using 68Ga-HBED-CC PSMA-PET/CT: A planning study based on histopathology reference. Zamboglou C, Sachpazidis I, Koubar K, Drendel V, Wiehle R, Kirste S, Mix M, Schiller F, Mavroidis P, Meyer PT, Werner M, Grosu AL, Baltas D. Radiother Oncol; 2017 Jun; 123(3):472-477. PubMed ID: 28499607 [Abstract] [Full Text] [Related]
13. Validation of different PSMA-PET/CT-based contouring techniques for intraprostatic tumor definition using histopathology as standard of reference. Zamboglou C, Fassbender TF, Steffan L, Schiller F, Fechter T, Carles M, Kiefer S, Rischke HC, Reichel K, Schmidt-Hegemann NS, Ilhan H, Chirindel AF, Nicolas G, Henkenberens C, Derlin T, Bronsert P, Mavroidis P, Chen RC, Meyer PT, Ruf J, Grosu AL. Radiother Oncol; 2019 Dec; 141():208-213. PubMed ID: 31431386 [Abstract] [Full Text] [Related]
14. 68Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis. von Eyben FE, Picchio M, von Eyben R, Rhee H, Bauman G. Eur Urol Focus; 2018 Sep; 4(5):686-693. PubMed ID: 28753806 [Abstract] [Full Text] [Related]
15. Improved specificity with 68Ga PSMA PET/CT to detect clinically significant lesions "invisible" on multiparametric MRI of the prostate: a single institution comparative analysis with radical prostatectomy histology. Donato P, Roberts MJ, Morton A, Kyle S, Coughlin G, Esler R, Dunglison N, Gardiner RA, Yaxley J. Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):20-30. PubMed ID: 30229528 [Abstract] [Full Text] [Related]
16. Prospective Study of the Radiolabeled GRPR Antagonist BAY86-7548 for Positron Emission Tomography/Computed Tomography Imaging of Newly Diagnosed Prostate Cancer. Touijer KA, Michaud L, Alvarez HAV, Gopalan A, Kossatz S, Gonen M, Beattie B, Sandler I, Lyaschenko S, Eastham JA, Scardino PT, Hricak H, Weber WA. Eur Urol Oncol; 2019 Mar; 2(2):166-173. PubMed ID: 31017093 [Abstract] [Full Text] [Related]
17. Head-to-Head Comparison of 18F-PSMA-1007 Positron Emission Tomography/Computed Tomography and Multiparametric Magnetic Resonance Imaging with Whole-mount Histopathology as Reference in Localisation and Staging of Primary Prostate Cancer. Exterkate L, Hermsen R, Küsters-Vandevelde HVN, Prette JF, Baas DJH, Somford DM, van Basten JA. Eur Urol Oncol; 2023 Dec; 6(6):574-581. PubMed ID: 37230883 [Abstract] [Full Text] [Related]
18. Whole-Body Integrated [68Ga]PSMA-11-PET/MR Imaging in Patients with Recurrent Prostate Cancer: Comparison with Whole-Body PET/CT as the Standard of Reference. Guberina N, Hetkamp P, Ruebben H, Fendler W, Grueneisen J, Suntharalingam S, Kirchner J, Puellen L, Harke N, Radtke JP, Umutlu L, Hadaschik BA, Herrmann K, Forsting M, Wetter A. Mol Imaging Biol; 2020 Jun; 22(3):788-796. PubMed ID: 31482413 [Abstract] [Full Text] [Related]